Physician profile
Ravi Kumar Moparty
NPI 1881664142
$596.52
in general payments reported to CMS, 2019-2025
17 companies · $50.08 in 2025
The $50.08 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $138 · 2023: $48.49 · 2024: $191 · 2025: $50.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $169.16 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.94 | 2019-2020 | |
| Gilead Sciences, INC. | $83.20 | 2019 | |
| Janssen Biotech, INC. | $50.19 | 2019-2023 | Simponi, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $46.23 | 2020-2024 | Gattex |
| Romark Laboratories, Lc | $44.23 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $32.17 | 2020-2023 | Linzess |
| Qol Medical, LLC | $25.08 | 2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $25.00 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $23.11 | 2020 | |
| Allergan, INC. | $12.21 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Moparty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.